<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890966</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-102</org_study_id>
    <nct_id>NCT02890966</nct_id>
  </id_info>
  <brief_title>Multiple Dose Study of SHR4640 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SHR4640 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the tolerance, pharmacokinetic and pharmacodynamic&#xD;
      properties of multiple dose adminstration of SHR4640 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Clinical significant changes from baseline up to Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration(Cmax)(of single dose and at stable status)</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve(AUC)(of single dose and at stable status)</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-time(T1/2)(of single dose and at stable status)</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the peak plasma concentration(Tmax)(of single dose and at stable status)</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum uric acid concentration from baseline</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urinary uric acid excretion from baseline</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Gout; Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg SHR4640 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5mg SHR4640 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg SHR4640 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg SHR4640 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640</intervention_name>
    <description>Day1~Day7:oral administration</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Day1~Day7:oral administration</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 and 55, male;&#xD;
&#xD;
          2. Body weight≥50, BMI:19-25kg/m2;&#xD;
&#xD;
        3.4 mg/dL≤Screening serum urate level≤7 mg/dL;&#xD;
&#xD;
        4.Medically stable based on physical examination, laboratory results, vital sign&#xD;
        measurements, 12-lead electrocardiogram, abdomen B-ultrasound and Chest X-ray examination&#xD;
        at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serum creatinine&gt;upper limits of normal(ULN);&#xD;
&#xD;
          2. Alanine aminotransferase and/or Aspartate aminotransferase&gt;2×ULN, total&#xD;
             bilirubin&gt;1.5×ULN, glutamyltransferase&gt;3×ULN;&#xD;
&#xD;
          3. History of hyperuricemia or gout;&#xD;
&#xD;
          4. History or suspicion of kidney stones;&#xD;
&#xD;
          5. Positive results for hepatitis B surface antigen, hepatitis C antibody, HIV antibody,&#xD;
             syphilis antibody test.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The South West Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR4640 pharmacokinetics pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

